MELVILLE, N.Y., Dec. 16, 2019 /PRNewswire/ — Nikon Instruments Inc., innovator of advanced microscope systems, today announced NIS.ai, a powerful image analysis and processing module for NIS-Elements that leverages Deep Learning and Artificial Intelligence. NIS.ai is a suite of new AI-based processing tools that utilizes convolutional neural networks to learn from small training datasets supplied by the user. The training results can then be easily applied to process and analyze huge volumes of data, enabling researchers to increase throughput and expand their application limits.
NIS.ai includes a suite of applications for predictive imaging, image segmentation and processing:
“The application of Deep Learning and AI to biomedical imaging is extremely powerful, and opening up unseen possibilities,” said Steve Ross, Ph.D., Director, Products & Marketing, Nikon Instruments Inc. “With NIS.ai, researchers can easily apply deep learning to extract meaningful, unbiased data from large, complex datasets.”
To learn more about NIS.ai, visit: https://www.microscope.healthcare.nikon.com/nis-ai
About Nikon Instruments Inc.
Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. Cutting-edge instruments include microscopes, digital imaging products and software. For more information, visit www.microscope.healthcare.nikon.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/nikon-announces-artificial-intelligence-ai-for-predictive-imaging-image-segmentation-and-processing-300975257.html
SOURCE Nikon Instruments Inc.
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…